



BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015.

Tel. : 0731-2723016 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Factory : Plot No. 8, Sector - III, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.) PIN - 454 775

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2426718 • CIN : L24233MP1985PLC002709

Date: 14th February, 2023

To,
The Company Secretary,
Corporate Compliance Department
The National Stock Exchange of India
Limited
Bandra Kurla Complex, Mumbai

To,
The Company Secretary
Corporate Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, P.J. Tower, Mumbai

Subject: Submission of Un-Audited Financial Results for the quarter and nine months ended on 31st December, 2022 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM, ISIN: INE829A01014.

Dear Sir/Madam,

This is in continuation of our letter dated 7th February, 2023 regarding information of Board Meeting for consideration and approval of Un-audited Financial Results for the quarter as well as nine months ended 31st December, 2022.

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we are hereby enclosing Un-Audited Financial Results together with Limited Review Report thereon for the quarter as well as nine months ended on 31st December, 2022 duly approved by the Board of Directors of the Company at its meeting held today i.e. Tuesday, 14th February, 2023 at the Registered Office of the Company.

Further, above Un-Audited Financial results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net. The Extract of aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper.

You are requested to kindly take on above said results for your reference and record.

Yours faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

SHWETA VERMA
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO. A70184
Enclosed: a/a

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2022

Sr No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		3 months ended on 31/12/2022	Previous 3 months ended on 30/09/2022	Corresponding 3 months ended on 31/12/2021	Year to date figures for Current period ended 31/12/2022	Year to date figures for Previous Year ended 31/12/2021	Previous Year ended on 31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operation	149.44	261.96	163.02	1641.95	2073.68	2238.23
II	Other Income	2.37	2.35	6.85	6.40	12.02	15.03
III	Total Income (I + II)	151.81	264.30	169.87	1648.36	2085.70	2253.26
IV	Expenses						
	(a) Cost of materials consumed	115.96	77.55	39.95	259.17	186.45	226.76
	(b) Purchases of stock-in-trade	2.75	138.27	56.34	1189.05	1355.00	1360.27
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(22.34)	(2.26)	(16.84)	16.77	307.94	359.01
	(d) Employee benefits expense	14.93	14.49	17.72	44.51	55.07	78.67
	(e) Finance Cost	1.06	1.06	1.09	3.25	3.03	4.06
	(f) Depreciation and Amortisation Expense	10.69	10.69	10.30	32.06	30.89	42.75
	(g) Other Expenses						
	1. Manufacturing Expenses	10.79	10.90	10.60	32.48	26.93	41.48
	2. Administrative Expenses	3.10	5.73	5.42	19.14	19.93	34.85
	3. Selling and Distribution Expenses	1.49	1.79	1.25	4.91	3.26	3.92
	Total expenses (IV)	138.43	258.22	125.83	1601.35	1988.52	2151.77
V	Profit/ (Loss) before exceptional items and tax (III-IV)	13.37	6.08	44.04	47.01	97.19	101.49
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V - VI)	13.37	6.08	44.04	47.01	97.19	101.49
VIII	Tax expense:						
	(1) Current tax	3.36	1.53	10.00	11.83	24.49	27.10
	(2) Deferred tax Credit/ (Charge)	0.00	0.00	0.00	0.00	0.00	4.55
IX	Profit/(Loss) for the period from continuing operation (VII-VIII)	10.01	4.55	34.04	35.18	72.70	69.84
X	Profit/(Loss) from dis-continued operation	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/ (Loss) for the period (IX+XII)	10.01	4.55	34.04	35.18	72.70	69.84
XIV	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	1.35
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	(0.34)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	10.01	4.55	34.04	35.18	72.70	70.86
XVI	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XVII	Reserves (Excluding Revaluation Reserve)						(319.82)

Rane


Biofil Chemicals and Pharmaceuticals Limited
INDORE


XVIII	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.06	0.03	0.21	0.22	0.45	0.44
	(2) Diluted (Rs)	0.06	0.03	0.21	0.22	0.45	0.44
XIX	Earnings Per Equity Share (for discontinued operation)						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
XX	Earnings Per Equity Share (for continuing & discontinued operation)						
	(1) Basic (Rs)	0.06	0.03	0.21	0.22	0.45	0.44
	(2) Diluted (Rs)	0.06	0.03	0.21	0.22	0.45	0.44

- The above unaudited financial results for the Quarter and nine month ended dec. 31, 2022 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on February 14, 2023. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
 - The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
 - Pharma Division
 - Chemicals Division.
 - The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
 - The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.

Date : 14-02-2023
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.


RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)






Biofil Chemicals and Pharmaceuticals Limited
Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709
Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718,
Website: www.biofilgroup.net

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND NINE MONTH ENDED 31ST DECEMBER, 2022

		(Amount in Lakhs)				
S.No.	Segment Revenue	Quarter Ended			Nine Month Ended	
		3 Month Ended 31/12/2022	Preceeding 3 Month Ended 30/09/2022	Correspondin g 3 months ended in the previous year (31/12/2021)	Year to date figures for current period ended (31/12/2022)	Year to date figures for the previous year ended (31/12/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
						Previous Year ended March 31 2022 Audited
1	Segment Revenue					
	Pharma Unit	1.33	141.94	106.60	1,204.45	1,880.11
	Chemicals Division	148.11	120.02	56.42	437.50	193.58
						1,900.52
	Net Sales/ Income From Operations	149.44	261.96	163.02	1,641.95	2,073.68
						2,238.23
2	Segment Results					
	Pharma Unit	(11.95)	(13.87)	40.56	(28.59)	109.76
	Chemicals Division	26.35	21.00	4.04	78.78	(11.12)
						98.70
	Total Segment Profit Before Tax & Interest	14.40	7.13	44.61	50.19	98.64
						103.33
	Interest Income	0.03	0.01	0.53	0.05	1.58
	Finance Cost	1.06	1.05	1.09	3.23	3.03
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	13.37	6.08	44.04	47.01	97.19
						101.49
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	873.87	2,012.21	2528.41	873.87	2,528.41
	Chemicals Division	1,382.80	1,299.99	1196.39	1,382.80	1,196.39
	Total (A)	2,256.66	3,312.20	3,724.80	2,256.66	3,724.80
						1,873.22
	Segment Liabilities (B)					
	Pharma Division	346.31	1,454.74	1564.25	346.31	1,564.25
	Chemicals Division	191.71	148.51	464.95	191.71	464.95
						86.53
	Total (B)	538.02	1,603.26	2,029.20	538.02	2,029.20
						189.46
	Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	527.56	557.47	964.16	527.56	964.16
	Chemicals Division	1,191.09	1,151.47	731.44	1,191.09	731.44
						591.56
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,718.64	1,708.94	1,695.60	1,718.64	1,695.60
						1,683.77

Date : 14-02-2023
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.


RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)





Independent Auditor's Review Report on the Quarterly Unaudited and Year to Date Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with SEBI Circular No. CIRJCFD/CMDI/44/2019 dated March 29, 2019

To,
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 31st December, 2022 and year to date from 01st April, 2022 to 31st December, 2022. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.





We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the review and significant findings, including any significant deficiencies in internal control that we identify during our review.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Place: Indore

Date: 14th February, 2023

For Maheshwari & Gupta
Chartered Accountants
FRN: 0061790

CA Sunil Maheshwari
Partner

M No.403346

UDIN: 23403346BGUKCV6191

